A novel technique for treating GBM first underwent a phase 1 clinical trial with patients who had recurrence of their cancers ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to WP1122 for the treatment of glioblastoma multiforme, according to a ...

The glioblastoma multiforme (GBM) treatment market size is on a steep growth trajectory, rising from $2.73 billion in 2025 to ...

In 2025, the market was valued at $2.7 billion, projected to reach $2.92 billion in 2026, with a CAGR of 8.1%. This ...

Glioblastoma multiforme (GBM) is the most common and aggressive type of tumor arising from star shaped cells called as astrocytes that make up supportive tissue of the brain. GBM has long baffled ...

At Novocure, we are very proud of our ongoing commitment and dedication to improving the lives of people with brain cancer. Our patients, their families and caregivers are at the heart of everything ...

Glioblastoma multiforme is the most common malignant primary brain tumor in adults. Mean progression-free survival is just over 6 months; treatment with surgical resection, chemotherapy, and radiation ...

A NUMBER of reports have appeared in the literature in recent years on the condition known as the Stevens-Johnson syndrome. The numerous descriptive names attached to its multiple manifestations have ...

Please provide your email address to receive an email when new articles are posted on . LP-184 (Lantern Pharma) is a next-generation alkylating agent designed to preferentially damage DNA in cancer ...